EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Regulatory Admission Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied